Klotho Neurosciences said it has initiated development of two genomics-based diagnostic tests aimed at assessing biological aging and supporting its clinical trials and longevity services. The company is developing a blood-based quantitative DNA methylation assay to measure methylation of the alpha-Klotho gene, and an AI-enabled “Klotho Clock” that analyzes DNA and mRNA sequences of Klotho and eight other longevity-associated genes to help link biological and chronological age. The announcement describes ongoing development and a prototype expected in 2026; no research results were reported as already presented.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Klotho Neuroscience Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202602240800PR_NEWS_USPR_____LA92592) on February 24, 2026, and is solely responsible for the information contained therein.
Comments